Search

Displaying results 2631 - 2640 of 4438 in total
  1. Drug

    HGTV-43

    go.drugbank.com/drugs/DB05807
    Experimental

    HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.

  2. Drug

    Aldosterone

    go.drugbank.com/drugs/DB04630
    Investigational

    A hormone secreted by the adrenal cortex that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium.

  3. Drug

    Rupintrivir

    go.drugbank.com/drugs/DB05102
    Experimental

    It is designed to combat colds caused by rhinovirus.

  4. Drug

    Cytisine

    go.drugbank.com/drugs/DB09028
    Investigational

    Recent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost.

  5. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

  6. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

  7. Drug

    Talopram

    go.drugbank.com/drugs/DB09190
    Experimental

    It was researched in the 1960s and 1970s but never marketed.

  8. Drug

    Demegestone

    go.drugbank.com/drugs/DB13857
    Experimental

    It was previously marketed in France as Lutionex, but has since been discontinued.

  9. Drug

    Oteseconazole

    go.drugbank.com/drugs/DB13055
    ApprovedInvestigational

    [L41635] This drug was approved by the FDA on April 26, 2022.[L41645] … [L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal candidiasis (RVVC).

  10. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [L46287] It was fully approved by the EMA in May 2023.[L46596] … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.